Cancer vaccine

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:00am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Intravacc to In-license CimCure's iBoost Technology, Expanding its Vaccine Platform Portfolio

Wednesday, July 1, 2020 - 8:01am

This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.

Key Points: 
  • This technology also enables Intravacc to expand its translational expertise towards the development of cancer vaccines.
  • iBoost is currently applied to elicit antibody responses against the tumor vasculature, a strategy that conquers the problem of drug resistance.
  • By using the patented iBoost technology, Intravacc and CimCure are also involved in the joint development of a COVID-19 vaccine.
  • Intravacc also has its own proprietary vaccine platform, and established state-of-the-art research and (GMP) production facilities.

Polynoma Receives FDA Fast Track Designation for its Melanoma Cancer Vaccine Seviprotimut-L

Tuesday, June 23, 2020 - 12:00pm

"The Fast Track designation by the FDA provides further validation of seviprotimut-L as a potential new and important cancer vaccine for patients with localized melanoma," said Alan Yu, Chairman of Polynoma and Vice President & Chief Operating Officer at CK Life Sciences.

Key Points: 
  • "The Fast Track designation by the FDA provides further validation of seviprotimut-L as a potential new and important cancer vaccine for patients with localized melanoma," said Alan Yu, Chairman of Polynoma and Vice President & Chief Operating Officer at CK Life Sciences.
  • Benefits of Fast Track designation include more frequent communication with the FDA, a rolling submission of the marketing application, and eligibility for Priority Review and Accelerated Approval, if relevant criteria are met.
  • The interval between progression from Stage II to Stage III/IV melanoma marks a critical therapeutic intervention point to improve survival.
  • Seviprotimut-L is an allogeneic, polyvalent, partially purified shed melanoma antigen vaccine derived from three proprietary human melanoma cell lines.

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Wednesday, June 17, 2020 - 3:00pm

Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.

Key Points: 
  • Saint-Gobain Life Sciences, Kanyr Pharma Inc., the RI-MUHC and McGill University have formed a new interdisciplinary consortium to make this technology more accessible.
  • In this project, dendritic cell cancer vaccines will be generated in Saint-Gobains VueLife C Series FEP bags.
  • View the full release here: https://www.businesswire.com/news/home/20200617005121/en/
    Interdisciplinary partnership between Saint-Gobain, Kanyr Pharma, and McGill in the development of optimized culture environments for dendritic cell cancer vaccines.
  • The ImmunyrTM technology was developed by Kanyr Pharma to activate each patients own immune system to target several types of cancer.

UbiVac Announces Clinical Trial Collaboration with Bristol Myers Squibb on Combination Immunotherapy for Advanced Triple Negative Breast Cancer

Tuesday, June 9, 2020 - 4:00pm

The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.

Key Points: 
  • The Phase 1b multicenter trial will test the hypothesis that combination immunotherapy with the DPV-001 cancer vaccine and anti-OX40 will augment anticancer immunity in patients with advanced triple negative breast cancer.
  • Triple Negative Breast Cancer is negative for estrogen receptors, progesterone receptors and HER2 receptors, and therefore treatment options are limited.
  • We believe that cutting-edge immunotherapy combinations have the potential to induce long-lasting anticancer immunity and translate into clinical responses in patients with triple negative breast cancer.
  • UbiVac is a privately held, clinical stage immunotherapy company engaged in the research and development of therapeutic vaccines to combat cancer.

Global Cancer Vaccine Partnering Deals Collection 2010-2020: Insights Into the Trends, Players and Financials of 290+ Deal Records

Tuesday, May 19, 2020 - 3:30pm

This report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Key Points: 
  • This report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
  • The report takes the reader through a comprehensive review Cancer Vaccine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Cancer Vaccine partnering deals.
  • Chapter 6 provides a comprehensive and detailed review of Cancer Vaccine partnering deals signed and announced since Jan 2010.
  • A comprehensive series of appendices is provided organized by Cancer Vaccine partnering company A-Z, stage of development, deal type, and therapy focus.

SQZ Biotech Closes $65 Million Series D Financing

Monday, May 18, 2020 - 12:00pm

SQZ Biotechnologies Company (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the completion of a $65 million Series D preferred stock financing.

Key Points: 
  • SQZ Biotechnologies Company (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the completion of a $65 million Series D preferred stock financing.
  • Our progress in oncology and recent expansion into the infectious disease space exemplifies the broad potential of the SQZ platforms.
  • The company is currently progressing its SQZ antigen presenting cell (SQZ APC) platform for oncology, a novel cancer vaccine, in a Phase 1 trial of SQZ-PBMC-HPV for HPV+ tumors.
  • SQZ Biotech is a privately held clinical stage company developing transformative cell therapy candidates for patients with cancer and other serious diseases.

Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Friday, May 15, 2020 - 6:10am

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NEC's Neoantigen Prediction System.
  • For more information, visit NEC at https://www.nec.com.For additional information, please also visit NEC Laboratories Europe GmbH at: http://www.neclab.eu

Transgene and NEC Demonstrate High Accuracy of AI-Based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050

Friday, May 15, 2020 - 6:30am

To evaluate the accuracy of the prediction, samples from cancer patients were collected.

Key Points: 
  • To evaluate the accuracy of the prediction, samples from cancer patients were collected.
  • Title of the poster: Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
    The abstract can be downloaded on the AACR website.
  • This virus-based therapeutic vaccine encodes neoantigens (patient-specific mutations) identified and selected by NECs Neoantigen Prediction System.
  • myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors.

Therapeutic Vaccines Industry Analysis and Forecast 2015-2025 (COVID-19 Adjusted)

Thursday, May 7, 2020 - 5:30pm

The Global Therapeutic Vaccines Market is expected to grow at a double digit CAGR during the forecast period, on account of increasing awareness in the population about prevalence of fatal and chronic diseases.

Key Points: 
  • The Global Therapeutic Vaccines Market is expected to grow at a double digit CAGR during the forecast period, on account of increasing awareness in the population about prevalence of fatal and chronic diseases.
  • Since vaccines are prepared for a special type of disease, it can be said that the market is the demand-based market.
  • The type segment is further segregated into addiction vaccines, auto immune disease vaccines, neurological disease vaccines, cancer vaccines, infectious disease vaccine and others.
  • The companies operating in the Global Therapeutic Vaccines Market are adoption inorganic and organic growth strategies to increase their share in the market.